{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:46:22Z","timestamp":1790552782197,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.urolonc.2020.09.031","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T16:48:07Z","timestamp":1606582087000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"John P.","family":"Sfakianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berengere","family":"Salome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Daza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0001","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","article-title":"BCG-induced trained immunity: can it offer protection against COVID-19?","volume":"20","author":"O'Neill","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0002","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0003","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2020.09.031_bib0004","first-page":"1133","article-title":"Treatment of superficial bladder cancer","volume":"122","author":"Morales","year":"1980","journal-title":"Can Med Assoc J"},{"issue":"5","key":"10.1016\/j.urolonc.2020.09.031_bib0005","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical Bacillus Calmette-Guerin immunotherapy: are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2020.09.031_bib0006","first-page":"838","article-title":"Bladder cancer: a disease ripe for major advances","volume":"12","author":"Park","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0008","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","article-title":"Bacillus Calmette-Guerin immunotherapy for genitourinary cancer","volume":"112","author":"Gandhi","year":"2013","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.urolonc.2020.09.031_bib0009","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","article-title":"Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer","volume":"17","author":"van Puffelen","year":"2020","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clim.2014.10.005","article-title":"BCG-induced trained immunity in NK cells: role for non-specific protection to infection","volume":"155","author":"Kleinnijenhuis","year":"2014","journal-title":"Clin Immunol"},{"issue":"Suppl 3","key":"10.1016\/j.urolonc.2020.09.031_bib0011","doi-asserted-by":"crossref","first-page":"iii6","DOI":"10.1136\/ard.60.90003.iii6","article-title":"Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages","volume":"60","author":"Jones","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0012","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1189\/jlb.69.6.1036","article-title":"Different Toll-like receptor agonists induce distinct macrophage responses","volume":"69","author":"Jones","year":"2001","journal-title":"J Leukoc Biol"},{"issue":"13","key":"10.1016\/j.urolonc.2020.09.031_bib0013","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.molimm.2005.12.004","article-title":"Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA","volume":"43","author":"Lee","year":"2006","journal-title":"Mol Immunol"},{"issue":"12","key":"10.1016\/j.urolonc.2020.09.031_bib0014","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1128\/IAI.68.12.6883-6890.2000","article-title":"Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin: involvement of toll-like receptors","volume":"68","author":"Tsuji","year":"2000","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1462-5822.2010.01544.x","article-title":"NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages","volume":"13","author":"Brooks","year":"2011","journal-title":"Cell Microbiol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13238-016-0326-x","article-title":"LRRK2 enhances Nod1\/2-mediated inflammatory cytokine production by promoting Rip2 phosphorylation","volume":"8","author":"Yan","year":"2017","journal-title":"Protein Cell"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0017","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.immuni.2014.08.005","article-title":"Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria","volume":"41","author":"Yonekawa","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2014.02.006","article-title":"Innate immune memory: towards a better understanding of host defense mechanisms","volume":"29","author":"Quintin","year":"2014","journal-title":"Curr Opin Immunol"},{"issue":"6284","key":"10.1016\/j.urolonc.2020.09.031_bib0019","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fpubh.2018.00013","article-title":"National immunization campaigns with oral polio vaccine reduce all-cause mortality: a natural experiment within seven randomized trials","volume":"6","author":"Andersen","year":"2018","journal-title":"Front Public Health"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0021","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3389\/fimmu.2019.02631","article-title":"Heterologous immunity: role in natural and vaccine-induced resistance to infections","volume":"10","author":"Agrawal","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2017.12.010","article-title":"BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity","volume":"23","author":"Arts","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0023","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0024","series-title":"L'infection bacillaire et la tuberculose chez l'homme et chez les animaux","author":"Calmette","year":"1920"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/infdis\/jiy544","article-title":"Early BCG vaccination, hospitalizations, and hospital deaths: analysis of a secondary outcome in 3 randomized trials from Guinea-Bissau","volume":"219","author":"Schaltz-Buchholzer","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0026","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.1931.02720270060030","article-title":"Preventive vaccination against tuberculosis with BC G and the Lubeck casualties","volume":"96","author":"Calmette","year":"1931","journal-title":"J Amer Med Assoc"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-0028-1124261","article-title":"Immunization and general death rate of infants","volume":"57","author":"Calmette","year":"1931","journal-title":"Deut Med Wochenschr"},{"issue":"7-8","key":"10.1016\/j.urolonc.2020.09.031_bib0028","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0264-410X(98)00277-1","article-title":"A historical and molecular phylogeny of BCG strains","volume":"17","author":"Behr","year":"1999","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.urolonc.2020.09.031_bib0029","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis \u2013 meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA-J Am Med Assoc"},{"issue":"6284","key":"10.1016\/j.urolonc.2020.09.031_bib0030","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.urolonc.2020.09.031_bib0031","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1128\/JVI.02393-08","article-title":"CD4 T-Cell-Mediated heterologous immunity between mycobacteria and poxviruses","volume":"83","author":"Mathurin","year":"2009","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0032","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0030-4220(76)90032-3","article-title":"BCG immunotherapy of a mucous-membrane malignant-melanoma - report of a case","volume":"42","author":"Pliskin","year":"1976","journal-title":"Oral Surg Oral Med O"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2017.00061","article-title":"Insights into local tumor microenvironment immune factors associated with regression of cutaneous melanoma metastases by Mycobacterium bovis Bacille Calmette-Guerin","volume":"7","author":"Yang","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0034","first-page":"1","article-title":"Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (vol 5, 68, 2017)","volume":"5","author":"Kamat","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02587182","article-title":"Combined treatment with BCG and chemotherapy for metastatic gastrointestinal cancer","volume":"20","author":"Falk","year":"1977","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0036","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0022-5347(17)53713-1","article-title":"Cytoreductive surgery and systemic Bacillus Calmette-Guerin therapy in metastatic renal cancer: a phase II trial","volume":"127","author":"Morales","year":"1982","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0037","first-page":"749","article-title":"Metastatic renal cell carcinoma regression after nephrectomy and BCG immunotherapy","volume":"6","author":"Dagnone","year":"1999","journal-title":"Can J Urol"},{"issue":"49","key":"10.1016\/j.urolonc.2020.09.031_bib0038","first-page":"351","article-title":"Prostate carcinoma: intratumor BCG immunotherapy","author":"Robinson","year":"1978","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0039","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9859021","article-title":"Prediction of Bacillus Calmette-Guerin response in patients with bladder cancer after transurethral resection of bladder tumor by using genetic variation based on genomic studies","volume":"2016","author":"Zhang","year":"2016","journal-title":"Biomed Res Int"},{"issue":"10","key":"10.1016\/j.urolonc.2020.09.031_bib0040","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1158\/1940-6207.CAPR-10-0035","article-title":"Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer","volume":"3","author":"Chen","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0041","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/pme.11.15","article-title":"Genetic susceptibility to bladder cancer risk and outcome","volume":"8","author":"Gu","year":"2011","journal-title":"Per Med"},{"issue":"12","key":"10.1016\/j.urolonc.2020.09.031_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.08.004","article-title":"Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy","volume":"35","author":"Poli","year":"2017","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0043","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/1097-0215(20000915)87:6<844::AID-IJC14>3.0.CO;2-5","article-title":"What are the immunologically active components of Bacille Calmette-Guerin in therapy of superficial bladder cancer?","volume":"87","author":"Zlotta","year":"2000","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2020.09.031_bib0044","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1074\/jbc.274.8.4521","article-title":"Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP","volume":"274","author":"Zhao","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbacli.2015.06.002","article-title":"Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): biological markers and simulation studies","volume":"4","author":"Kiselyov","year":"2015","journal-title":"BBA Clin"},{"issue":"8","key":"10.1016\/j.urolonc.2020.09.031_bib0046","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1172\/JCI89717","article-title":"ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence","volume":"127","author":"Chevalier","year":"2017","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0047","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01741603","article-title":"Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guerin","volume":"33","author":"De Boer","year":"1991","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0048","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","article-title":"Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"Bohle","year":"1990","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.09.031_bib0049","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0022-5347(17)45922-2","article-title":"Histological parameters and pitfalls in the interpretation of bladder biopsies in Bacillus Calmette-Guerin treatment of superficial bladder cancer","volume":"135","author":"Lage","year":"1986","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0050","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.eururo.2006.11.045","article-title":"The role of granulocytes following intravesical BCG prophylaxis","volume":"51","author":"Siracusano","year":"2007","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2020.09.031_bib0051","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Res"},{"issue":"53","key":"10.1016\/j.urolonc.2020.09.031_bib0052","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","article-title":"TRAIL and apoptosis induction by TNF-family death receptors","volume":"22","author":"Wang","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0053","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3892\/mmr.2016.4873","article-title":"Improved antitumor efficacy of neutrophils stimulated by Bacillus Calmette-Guerin","volume":"20","author":"Wang","year":"2019","journal-title":"Mol Med Rep"},{"issue":"5663","key":"10.1016\/j.urolonc.2020.09.031_bib0054","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2019.02.005","article-title":"BCG-induced formation of neutrophil extracellular traps play an important role in bladder cancer treatment","volume":"201","author":"Liu","year":"2019","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.06.010","article-title":"Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer","volume":"33","author":"Mano","year":"2015","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0057","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clgc.2018.07.003","article-title":"Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscle-invasive bladder cancer","volume":"16","author":"Vartolomei","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0058","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1590\/S1677-5538.IBJU.2015.0243","article-title":"Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study","volume":"42","author":"Favilla","year":"2016","journal-title":"Int Braz J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2020.09.031_bib0059","doi-asserted-by":"crossref","first-page":"12891","DOI":"10.18632\/oncotarget.14179","article-title":"Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor","volume":"8","author":"Kang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12894-018-0404-x","article-title":"Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer","volume":"18","author":"Getzler","year":"2018","journal-title":"BMC Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0061","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/s1677-5538.ibju.2018.0249","article-title":"Can neutrophil-to-lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?","volume":"45","author":"Racioppi","year":"2019","journal-title":"Int Braz J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0062","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0063","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.juro.2008.11.090","article-title":"Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation","volume":"181","author":"Takayama","year":"2009","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0064","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy","volume":"55","author":"Ayari","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0065","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/948098","article-title":"Macrophages in tumor microenvironments and the progression of tumors","volume":"2012","author":"Hao","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0066","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.1995.155","article-title":"Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing","volume":"71","author":"Pryor","year":"1995","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2020.09.031_bib0067","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1349-7006.2000.tb00978.x","article-title":"Enhancing effect of an inhibitor of nitric oxide synthesis on bacillus Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro","volume":"91","author":"Yamada","year":"2000","journal-title":"Jpn J Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0068","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0069","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2249.2006.03191.x","article-title":"Role of Th1-stimulating cytokines in bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells","volume":"146","author":"Luo","year":"2006","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.2010.04105.x","article-title":"Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells","volume":"160","author":"Luo","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0071","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","article-title":"Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and gamma-delta-T cells","volume":"14","author":"Naoe","year":"2007","journal-title":"Int J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2020.09.031_bib0072","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00262-008-0643-x","article-title":"A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth","volume":"58","author":"Higuchi","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0073","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"issue":"26","key":"10.1016\/j.urolonc.2020.09.031_bib0074","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/2326-6066.CIR-18-0671","article-title":"Intravesical Ty21a vaccine promotes dendritic cells and T cell-mediated tumor regression in the MB49 bladder cancer model","volume":"7","author":"Domingos-Pereira","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0076","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3389\/fimmu.2017.00796","article-title":"Deconvolution of the response to Bacillus Calmette-Guerin reveals NF-kappaB-induced cytokines as autocrine mediators of innate immunity","volume":"8","author":"Bisiaux","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0077","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer","volume":"181","author":"Bisiaux","year":"2009","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.09.031_bib0078","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0079","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J Urol"},{"issue":"3-4","key":"10.1016\/j.urolonc.2020.09.031_bib0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10555-009-9195-6","article-title":"The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder","volume":"28","author":"Rosevear","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0081","article-title":"Mycobacterium bovis bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cells","volume":"2010","author":"Luo","year":"2010","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0082","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0083","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","article-title":"Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis","volume":"19","author":"de Boer","year":"1991","journal-title":"Urol Res"},{"issue":"5","key":"10.1016\/j.urolonc.2020.09.031_bib0084","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0165-2478(91)90150-9","article-title":"Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines","volume":"27","author":"Wang","year":"1991","journal-title":"Immunol Lett"},{"key":"10.1016\/j.urolonc.2020.09.031_bib0086","first-page":"88","article-title":"Activation of natural killer cells during microbial infections","volume":"2","author":"Horowitz","year":"2011","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.09.031_bib0087","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/eji.201041180","article-title":"A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG","volume":"41","author":"Evans","year":"2011","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.urolonc.2020.09.031_bib0088","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.4049\/jimmunol.1000106","article-title":"Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes","volume":"184","author":"Horowitz","year":"2010","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0089","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nri2057","article-title":"Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens","volume":"7","author":"Newman","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0090","first-page":"1469","article-title":"Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer","volume":"17","author":"Sonoda","year":"2007","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0091","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","article-title":"Requirement of a thymus dependent immune response for BCG-mediated antitumor activity","volume":"137","author":"Ratliff","year":"1987","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0092","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000355628","article-title":"Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity","volume":"6","author":"Kleinnijenhuis","year":"2014","journal-title":"J Innate Immun"},{"issue":"5","key":"10.1016\/j.urolonc.2020.09.031_bib0093","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0094","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of Myeloid-Derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.09.031_bib0095","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0096","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000020170","article-title":"What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?","volume":"37","author":"Zlotta","year":"2000","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0097","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0098","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0099","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.031_bib0101","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-5347(01)65185-1","article-title":"Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer","volume":"157","author":"Zlotta","year":"1997","journal-title":"J Urol"},{"issue":"137","key":"10.1016\/j.urolonc.2020.09.031_bib0102","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.031_bib0103","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.juro.2017.12.057","article-title":"Purified protein derivative skin test prior to bacillus Calmette-Guerin therapy may have therapeutic impact in patients with nonmuscle invasive bladder cancer","volume":"199","author":"Niwa","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0104","article-title":"Priming with percutaneous bacillus Calmette-Guerin (BCG) prior to intravesical BCG treatment safely improves BCG-specific response in patients with bladder cancer","volume":"200","author":"Ji","year":"2018","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.031_bib0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical Bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2020.09.031_bib0106","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.031_bib0107","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.urolonc.2020.09.031_bib0108","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1086\/314072","article-title":"Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature","volume":"31","author":"Brewer","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"8369","key":"10.1016\/j.urolonc.2020.09.031_bib0109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(84)90072-2","article-title":"Incidence of childhood tuberculosis after neonatal BCG vaccination","volume":"1","author":"Curtis","year":"1984","journal-title":"Lancet"},{"issue":"6082","key":"10.1016\/j.urolonc.2020.09.031_bib0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/bmj.2.6082.293","article-title":"BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life","volume":"2","author":"Hart","year":"1977","journal-title":"Br Med J"},{"issue":"7788","key":"10.1016\/j.urolonc.2020.09.031_bib0111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"},{"issue":"1-2","key":"10.1016\/j.urolonc.2020.09.031_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.12.031","article-title":"BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis","volume":"172","author":"Kaufmann","year":"2018","journal-title":"Cell"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030466X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030466X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:50Z","timestamp":1761041930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392030466X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S107814392030466X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.09.031","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}